Skip to main content
SpringerLink
Log in

Bone-Targeted Therapy in Advanced Breast Cancer

  • Chapter
  • First Online:
Breast Cancer

  • 2137 Accesses

Abstract

The bone is one of the three most common metastatic sites of breast cancer. Bone metastatic disease has a favorable prognosis compared to visceral metastatic disease, but skeletal event (pain, pathologic fractures, hypercalcemia and spinal cord compression)-related morbidity and decreased quality of life have a large overall impact. Osteoclasts and the loss of equilibrium between osteoclasts and osteoblasts play major roles in bone metastasis. Bisphosphonates inhibit bone resorption by inducing apoptosis of osteoclasts. Denosumab is as a monoclonal antibody against receptor activator of nuclear factor (NF)-KB ligand, which is essential for osteoclast survival. To reduce the burden of bone metastasis, prevention is crucial in advanced cancer patients without skeletal involvement. However, given the available data regarding bisphosphonates in advanced breast cancer (ABC) without osseous involvement, international guidelines do not support the preventive use of bone-targeted agents. The toxicities of bisphosphonates and denosumab include hypocalcemia, renal toxicity, gastrointestinal disturbance and osteonecrosis of the jaw, which should be carefully reviewed when administering drugs and making decisions about dose, interval and duration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol. 2000;18:3925–35.

    Article  CAS  Google Scholar 

  2. Body J. Biphosphonates in breast cancer and other solid tumors. In: Mundy RD, Rubens RD, editors. Cancer and the skeleton. London: Martin Dunitz; 2000.

    Google Scholar 

  3. Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol. 2006;59:56–63.

    Article  Google Scholar 

  4. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.

    Article  CAS  Google Scholar 

  5. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–49.

    Article  CAS  Google Scholar 

  6. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285–93.

    Article  CAS  Google Scholar 

  7. Wong M, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer. 2011;3:35–60.

    PubMed  Google Scholar 

  8. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12:6222s–30s.

    Article  CAS  Google Scholar 

  9. Thompson K, Roelofs AJ, Jauhiainen M, Monkkonen H, Monkkonen J, Rogers MJ. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol. 2010;658:11–20.

    Article  CAS  Google Scholar 

  10. O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.

    PubMed  Google Scholar 

  11. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43.

    Article  CAS  Google Scholar 

  12. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014;15:114–22.

    Article  CAS  Google Scholar 

  13. Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:2062–81.

    Article  Google Scholar 

  14. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013;14:663–70.

    Article  CAS  Google Scholar 

  15. Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017;3:906–12.

    Article  Google Scholar 

  16. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317:48–58.

    Article  CAS  Google Scholar 

  17. Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol. 2011;7:381–3.

    Article  CAS  Google Scholar 

  18. Lipton A, Jacobs I. Denosumab: benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care. 2011;5:258–64.

    Article  Google Scholar 

  19. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.

    Article  CAS  Google Scholar 

  20. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.

    Article  CAS  Google Scholar 

  21. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.

    Article  CAS  Google Scholar 

  22. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017;35:3978–86.

    Article  Google Scholar 

  23. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663–7.

    Article  CAS  Google Scholar 

  24. van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, van Eck-Smit BC, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer. 1996;32A:450–4.

    Article  Google Scholar 

  25. Sheedy KC, Camara MI, Camacho PM. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr Pract. 2015;21:275–9.

    Article  Google Scholar 

  26. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281–9.

    Article  CAS  Google Scholar 

  27. Markowitz GS, Fine PL, D’Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39:1118–22.

    Article  Google Scholar 

  28. Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, American Society of Clinical Oncology, National Comprehensive Cancer Network, et al. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr. 2013;125:439–47.

    Article  CAS  Google Scholar 

  29. Prommer E. Palliative oncology: denosumab. Am J Hosp Palliat Care. 2015;32:568–72.

    Article  Google Scholar 

  30. Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care. 2014;9:332–6.

    Article  Google Scholar 

  31. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014;10:257–75.

    Article  CAS  Google Scholar 

  32. Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett. 2014;7:1997–2002.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology,, Dr. A. Y. Ankara Oncology Education and Research Hospital, Ankara, Turkey

    Ece Esin

  2. Department of Medical Oncology, Faculty of Medicine, Balkan Oncology Hospital, Trakya University of Medicine, Edirne, Turkey

    Irfan Cicin

Authors
  1. Ece Esin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irfan Cicin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irfan Cicin .

Editor information

Editors and Affiliations

  1. Internal Medicine, Medical Oncology, Istanbul Medical Faculty, Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. General Surgery, Istanbul Medical Faculty, Department of Surgery, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Surgical Oncology, Magee-Women’s Hospital, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Esin, E., Cicin, I. (2019). Bone-Targeted Therapy in Advanced Breast Cancer. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-96947-3_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96947-3_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96946-6

  • Online ISBN: 978-3-319-96947-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation